Resources
View resources about cytomegalovirus and CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) as well as the locations of our upcoming engagements.
Learn More About CYTOGAM With Resources for Your Practice, Institution, and Patients
Easily access printable resources and videos to help train staff on the importance of CMV prevention and educate your patients.
Downloadable and Viewable Materials
CYTOGAM Mechanism of Action Video
This animated video represents components of the mechanism of action of CYTOGAM as “characters” to dynamically illustrate the simultaneous steps that occur.1-3
Antiviral Effect of CMV Immune Globulin After Liver Transplantation5 – Poster Presentation
Dr. Jennifer Chow MD MS, FAST presents key findings from the Tufts Medical Center poster presented at the 2024 ATC meeting .5
Video Series: Cutting-Edge Strategies Against CMV: Breakthroughs in Hyperimmune Therapy
Science and Innovation Theater
Video 1: Kamada Inc., Hyperimmune Globulins, and the US Clinical Program Overview
Presented by Winston Ally, PharmD
Director, US Medical Affairs, Kamada Inc.
Time: 4:09 minutes
Video 2: Anti-CMV Strategies and Immune Response in Lung Transplantation
Presented by Lorenzo Zaffiri, MD, PhD
Associate Medical Director, Lung Transplant Program, Department of Medicine, Cedars-Sinai
Assistant Professor, Department of Medicine
Time: 14:25 minutes
Video Series: Innovative Approcahes to CMV Management in SOT: Transforming the Role of CYTOGAM
Science and Innovation Theater
Video 3: The Current State of CMV in SOT
Presented by Marie M. Budev DO, MPH FCCP
Medical Director Lung, Heart-Lung Transplant Program, Department of Pulmonary Medicine, Cleveland Clinic
Professor, Lerner College of Medicine
Time: 15:36 minutes
Video 4: Kamada Inc., Supporting Innovation in SOT
Presented by Winston Ally, PharmD
Director, US Medical Affairs, Kamada Inc.
Time: 11:36 minutes
Emerging Clinical Data: “Long-Term Outcomes Among Lung Transplant Recipients
With High-Risk Cytomegalovirus Mismatch Managed With a Multimodality Regimen”
This single-center, retrospective, long-term follow-up, real-world data study demonstrates that a multimodal approach of adding CYTOGAM to standard antiviral prophylaxis in CMV D+/R- lung transplant recipients attenuated the negative impact of CMV serostatus by enabling high-risk patients to achieve long-term survival and CLAD outcomes similar to lower-risk patients5.
ISHLT Voices Podcast Series: “Unlocking Hyperimmunes – Emerging Clinical Data about Cytogam”
In this episode of ISHLT Voices, you’ll hear a discussion on the utilization of CYTOGAM in solid organ transplantation (SOT) from the following speakers: Martin Zamora, MD, Medical Director of Lung Transplantation, Advent Health, Orlando, FL. Lorenzo Zaffiri, MD, PhD, Medical Director of Lung Transplantation, Emory University, Atlanta, GA and Robert Gottlieb, MD, PhD, FACC, Transplant Cardiologist, Baylor Scott White, Dallas, TX.
Emerging Clinical Data: “Antiviral Effect of Cytomegalovirus Immune Globulin after Liver Transplantation in Patients who were not CMV Donor Positive/Recipient Negative”
This post-hoc analysis by Tufts Medical Center purpose was to explore the antiviral effect of CYTOGAM administration post-liver transplant on CMV viral load levels and CMV disease severity in intermediate and low-risk patients.5 A full publication is expected in early 2025.
Patient Resource: Understanding Cytomegalovirus (CMV)
This easy-to-read guide helps patients understand CMV symptoms, monitoring, and prevention. It also emphasizes the importance of compliance with prescribed post-transplant treatments and diagnostic monitoring.
CYTOGAM Brochure
This 2-page brochure contains an overview of CYTOGAM with an emphasis on how its complementary MOA, in conjunction with an antiviral, combines to provide CMV prophylaxis. 1,2
Upcoming Events
CYTOGAM offers webinars to healthcare providers and their staff periodically. Additionally, Kamada Inc. participates annually in medical conferences in the United States and internationally. Events will be posted below as they become available.
International Transplant Nurses Society Annual Meeting
Discover Kamada’s latest updates at the ITNS Annual Meeting, October 3-5, 2025, in Philadelphia!
Our team will highlight emerging data on CYTOGAM’s role in preventing CMV disease in SOT patients. Visit our booth to see how CYTOGAM can help your patients.
Don’t miss out! Learn more
CMV Stream 2025 is now available on demand
Watch the recording now at: www.cmvstream.com
CMV Stream 2025 featured an in-depth discussion on challenging issues and open questions
from the recently published 4th International Consensus Guidelines on the Management of CMV in SOT.
If you missed the live broadcast: click here!
References: 1. Grossi PA, Mohacsi P, Szabolcs Z, Potena L. Cytomegalovirus immunoglobulin after thoracic transplantation: an overview. Transplantation. 2016;100:S1-S4. 2. Carbone J. The immunology of posttransplant CMV infection: potential effect of CMV immunoglobulins on distinct components of the immune response to CMV. Transplantation. 2016;100: S11-S18. 3. Deml L, Huber CM, Barabas S, Spindler T, Cozzi E, Grossi P. Stimulatory effect of CMV immunoglobulin on innate immunity and on the immunogenicity of CMV antigens. Transplant Direct. 2021;7:e781. doi:10.1097/TXD.0000000000001236 4. Banga N, Kanade R, Kappalayil A, Timofte I, Lawrence A, Bollineni S, Kaza V, Torres F. Long-Term Outcomes Among Lung Transplant Recipients With High-Risk Cytomegalovirus Mismatch Managed With a Multimodality Regimen. Clin Transplant. 2025 Jul;39(7):e70219. doi: 10.1111/ctr.70219. PMID: 40583605; PMCID: PMC12207284. 5. Jennifer K.L. Chow, Laura A. McDermott, David R. Snydman. Antiviral Effect of Cytomegalovirus Immune Globulin after Liver Transplantation in Patients who were not CMV Donor Positive/Recipient Negative. Poster presented at: ATC; June 1-5, 2024; Philadelphia, PA.